Stocks · News reference
Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
CORRECTION: Biodexa Pharmaceuticals Announces 1-For-8 Reverse ADS Split, Effective October 26
On October 8, 2026, Biodexa Pharmaceuticals PLC (the "Company") announced a ratio change of its American Depositary Shares ("ADSs") from one (1) ADS representing fifty (50) of its ordinary shares, to a